Ratings PolyPeptide Group AG London S.E.

Equities

0AAJ

CH1110760852

Delayed London S.E. Other stock markets 05:29:00 07/05/2024 pm IST			5-day change	1st Jan Change
31.25 ^CHF	+90.20%		-3.85%	+78.37%

13/05	Donaldson Company, Inc. and PolyPeptide Group AG Partners to Improve Sustainability in Peptide Manufacturing with Solvent Recovery Technology	CI
12/03	PolyPeptide Group AG Provides Earnings Guidance for 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company has insufficient levels of profitability.
The company's enterprise value to sales, at 3.31 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
POLYPEPTIDE GROUP AG	+78.37%	121.52Cr	-
NOVO NORDISK A/S	+41.96%	63TCr	B
JOHNSON & JOHNSON	-7.15%	35TCr	C+
MERCK & CO., INC.	+18.77%	33TCr	B-
ABBVIE INC.	+8.79%	30TCr	C+
ASTRAZENECA PLC	+18.02%	25TCr	B+
ROCHE HOLDING AG	+1.27%	22TCr	A+
NOVARTIS AG	+11.95%	22TCr	B-
AMGEN INC.	+3.68%	16TCr	C+
PFIZER, INC.	-4.38%	16TCr	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes